The New Hep C Drug: PSI-7977 to Sofosbuvir

Recently (December 6th, 2013) Sofosbuvir was approved by US FDA for the treatment of Chronic Hepatitis C in combination with Ribavirin for dual therapy and with Ribavirin & Pegylated Interferon triple therapy for treatment-naive patients having HCV genotypes 1 and 4.

Sofosbuvir-PSI-7977-GS-7977

The drug is being marketed as Sovaldi by Gilead.

Leave a Reply

Your email address will not be published. Required fields are marked *